期刊文献+

HER2与CD163在胃癌中的表达及意义 被引量:3

Expression and clinical significance of HER2 and CD163 in human gastric cancer
暂未订购
导出
摘要 目的研究人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER2)与M2型巨噬细胞表面标志物分化抗原簇163(cluster of differentiation 163,CD163)在胃癌组织中的表达及意义。方法应用免疫组织化学方法检测45例胃癌和癌旁组织标本中HER2、CD163和CD68蛋白的表达,并将检测结果与患者临床病理资料相结合进行综合分析。结果胃癌组织中的CD163^+和CD68^+细胞数目高于癌旁组织(均P<0.05),HER2阳性表达在肿瘤p TNM分期、有无淋巴结转移等方面差异有统计学意义(均P<0.05)。CD163^+M2巨噬细胞数在肿瘤p TNM分期方面差异有统计学意义(P<0.05)。HER2蛋白表达与CD163^+M2性巨噬细胞数目存在相关性(r=0.61,P<0.05)。结论 HER2表达强度与M2型巨噬细胞数目存在相关性,二者是判断胃癌诊断、治疗及预后的重要参考指标。 Objective To investigate the expression and significance of human epidermal growth factor receptor-2(HER2) and M2-type macrophage surface marker cluster of differentiation 163( CD163) in human gastric cancer,and their relationship with clinicopathological features of the cancer. Methods The expression of HER2,CD163 and CD68 were examined by immunohistochemistry in 45 specimens of gastric cancer tissues and cancer-adjacent normal tissues. The association of their expression with clinicopathologic features was analyzed. Results The expressions of CD163 and CD68 in gastric cancer tissue were significantly higher than those in adjacent normal gastric tissues( P〈0. 05). The expression of HER2 protein in gastric cancer tissues differred in cases with different tumor p TNM staging and status of lymph node metastasis( P〈0. 05). Meanwhile,the number of CD163-+M2 macrophages differred in cases with different p TNM staging( P〈0. 05). Moreover,HER2 expression was positively correlated with the number of CD163-+M2 macrophages in gastric cancer tissue( r = 0. 61,P〈0. 05). Conclusion HER2 expression is correlated with the number of CD163-+M2 macrophages,and both may be used for diagnoses,treatment and prognosis of gastric cancer.
出处 《实用肿瘤杂志》 CAS 2016年第2期131-134,共4页 Journal of Practical Oncology
基金 湖州市科技局自然科学基金项目(2014YZB)
关键词 胃肿瘤/病理学 受体 表皮生长因子 巨噬细胞 抗原 CD 免疫组织化学 预后 stomach neoplasms/pathology receptor epidermal growth factor macrophages antigens CD immunohistochemistry prognosis
  • 相关文献

参考文献12

  • 1Xie SD,Xu CY,Shen JG, et al. HER-2/neu protein ex-pression in gastric cancer is associated with poor survival[J].Mol Med Rep,2009,2(6) :943 -946.
  • 2Sica A,Mantovani A. Macrophage plasticity and polariza-tion: in vivo veritas[ J]. J Clin Invest,2012,122(3) :787-795.
  • 3Sobin LH, Wittekind C. TNM classification of malignanttumours[ M]. 7thed. New York: John Wiley & Sons ,2009 :73 -77.
  • 4胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:103
  • 5Pollard JW. Tumor-educated macrophages promote tumorprogression and metastasis [ J ]. Nat Rev cancer, 2004, 4(1):71 -78.
  • 6Allgayer H,Babic R, Gruetzner KU, et al. C-erbB-2 is ofindependent prognostic relevance in gastric cancer and isassociated with expression of tumor-associated proteasesystems [J]. J Clin Oncol, 2000,18(11) :2201 - 2209.
  • 7Takehana T,Kunimoto K,Kono K,et al. Status of C-erbB2in gastric adenocarcinoma: a comparative study of immu-nohistochemistry fluorescence in situ hybridization and en-zyme-linked immunosorbent assay [J]. Int J Cancer,2002,98(6) :833 -837.
  • 8AP Cardoso,ML Pinto,AT Pinto,et al. Macrophages stim-ulate gastric and colorectal cancer invasion through EGFRY1086 , c-Src, Eekl/2 and Akt Phosphorylation and smallGTPase activity [ J ]. Oncogene, 2014, 33 ( 16 ) : 2123 -2133.
  • 9张锡(综述),薛英威(审校).胃癌Her-2的表达与靶向治疗[J].实用肿瘤学杂志,2014,28(2):177-181. 被引量:9
  • 10Geng Y, Wang J, Wang R, et al. Leptin and HER-2 areassociated with gastric cancer progression and prognosisof patients[ J ]. Biomed Pharmaother,2012 ,66 ( 6) ;419-424.

二级参考文献61

  • 1Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 3Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 4Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 5Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 6Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 7Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 8RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.
  • 9Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011, In press.
  • 10Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro- oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5 ) and two in situ hybridization methods ( FISH and SISH). Histopathology, 2011, 58 ( 3 ) : 383-394.

共引文献110

同被引文献10

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部